Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study.
infections
multiple sclerosis
relapses
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Jan 2023
28 Jan 2023
Historique:
received:
08
12
2022
revised:
06
01
2023
accepted:
12
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Many factors are believed to be positively associated with the incidence of relapses in people with multiple sclerosis (MS), including infections. However, their role is still controversial. We aimed to investigate whether symptomatic infections in people with MS increase the risk of relapse in the short, medium, or long term. We enrolled consecutive patients with relapsing MS (RMS) from October to December 2018. From enrolment up to September 2020, an online questionnaire investigating the occurrence of infections was sent via WhatsApp We enrolled 155 patients with RMS, and 88.38% of patients were treated with disease-modifying therapies. In the dataset, 126,381 total patient days, 78 relapses, and 1202 infections were recorded over a period of about 2 years. No increased risk of relapse after clinically manifest infections was found in the short-, medium-, or long-term period. No correlation was found between all infections and the number of relapses ( No associations between infections and relapses were observed, likely suggesting that disease-modifying therapies may protect against the risk of relapse potentially triggered by infections.
Sections du résumé
BACKGROUND
BACKGROUND
Many factors are believed to be positively associated with the incidence of relapses in people with multiple sclerosis (MS), including infections. However, their role is still controversial. We aimed to investigate whether symptomatic infections in people with MS increase the risk of relapse in the short, medium, or long term.
MATERIALS AND METHODS
METHODS
We enrolled consecutive patients with relapsing MS (RMS) from October to December 2018. From enrolment up to September 2020, an online questionnaire investigating the occurrence of infections was sent via WhatsApp
RESULTS
RESULTS
We enrolled 155 patients with RMS, and 88.38% of patients were treated with disease-modifying therapies. In the dataset, 126,381 total patient days, 78 relapses, and 1202 infections were recorded over a period of about 2 years. No increased risk of relapse after clinically manifest infections was found in the short-, medium-, or long-term period. No correlation was found between all infections and the number of relapses (
CONCLUSIONS
CONCLUSIONS
No associations between infections and relapses were observed, likely suggesting that disease-modifying therapies may protect against the risk of relapse potentially triggered by infections.
Identifiants
pubmed: 36769670
pii: jcm12031023
doi: 10.3390/jcm12031023
pmc: PMC9918238
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurology. 2006 Aug 22;67(4):652-9
pubmed: 16870812
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
Neurol Sci. 2018 Aug;39(8):1467-1470
pubmed: 29756179
Autoimmun Rev. 2021 Jun;20(6):102826
pubmed: 33878488
Neuroepidemiology. 2008;31(4):271-9
pubmed: 18971584
Ann Neurol. 1994;36 Suppl:S25-8
pubmed: 8017885
Neurol Ther. 2018 Jun;7(1):59-85
pubmed: 29243029
Crit Care Med. 2006 Oct;34(10):2576-82
pubmed: 16915108
Ann Neurol. 2010 May;67(5):618-24
pubmed: 20437559
Neuroepidemiology. 2015;44(4):199-214
pubmed: 25997994
Lancet. 1985 Jun 8;1(8441):1313-5
pubmed: 2860501
J Neurol. 1993 Jul;240(7):417-22
pubmed: 8410082
Drugs. 2000 Mar;59(3):401-10
pubmed: 10776827
Mult Scler J Exp Transl Clin. 2019 Feb 11;5(1):2055217319826598
pubmed: 30800416
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
BMJ. 2004 Mar 27;328(7442):731
pubmed: 15033880
Mult Scler. 2019 Jun;25(7):891-901
pubmed: 30638421
Mult Scler Relat Disord. 2016 Nov;10:169-173
pubmed: 27919484
Brain. 2022 Sep 14;145(9):3147-3161
pubmed: 35104840
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Front Immunol. 2020 May 06;11:781
pubmed: 32435244
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Ann Neurol. 2010 Aug;68(2):193-203
pubmed: 20695012
BMC Fam Pract. 2011 May 16;12:33
pubmed: 21575193
BMC Neurol. 2010 Nov 01;10:105
pubmed: 21040535
Neurol Sci. 2022 May;43(5):2935-2942
pubmed: 35092543
J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):736-41
pubmed: 9647301
Ann Neurol. 2014 Dec;76(6):880-90
pubmed: 25283272
Mult Scler Relat Disord. 2022 Dec;68:104395
pubmed: 36544324
Brain. 2002 May;125(Pt 5):952-60
pubmed: 11960885